BCLI · Brainstorm Cell Therapeutics Inc.
$0.98
+0.10 (+11.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Such conditions raise substantial doubts about the Company's ability to continue as a going concern. Management's plan includes raising funds from outside potential investors, however, as mentioned above, there is no assurance such funding will be available to the Company or that it will be obtained on terms favorable to the Company or will provide the Company with sufficient funds to meet its objectives.”View the 10-Q filed Aug 14, 2026
Market Cap
$10.92M
Shares
11.03M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | Co-Chief Executive Officer Uri Yablonka(\ ), Executive Vice President, Chief Business Officer, Secretary and Director | $1,007,725 |
| Ralph Kern | Former President & Former Chief Medical Officer | $833,192 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Stacy Lindborg | Co-Chief Executive Officer Uri Yablonka(\ ), Executive Vice President, Chief Business Officer, Secretary and Director | $851,543 |
| Ralph Kern | Former President & Former Chief Medical Officer | $812,559 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Ralph Kern | Former President & Former Chief Medical Officer | $938,833 |
| Stacy Lindborg | Co-Chief Executive Officer | $736,680 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Ralph Kern | President & Chief Medical Officer | $1,528,281 |
| Stacy Lindborg | EVP, Chief Development Officer | $867,505 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ibrahim B. Dagher | Executive Vice President and Chief Medical Officer | Resigned | 2026-07-30 |
| Jacob Frenkel | Chairman of the Board | Resigned | 2026-07-30 |
| Peter Pitts | Chief Strategic Regulatory Officer | Appointed | 2026-07-30 |
| Jacob Frenkel | director | Resigned | 2026-07-30 |
| Peter Pitts | Executive Chairman of the Board | Appointed | 2026-07-30 |
| Peter Pitts | director | Appointed | 2026-05-28 |
| Uri Yablonka | Director | Appointed | 2025-06-25 |
| Dr. Stacy Lindborg | Director | Appointed | 2025-06-25 |
| Dr. Anthony Polverino | Director | Appointed | 2025-06-25 |
| Nir Naor | Director | Appointed | 2025-06-25 |
| Dr. Jacob Frenkel | Director | Appointed | 2025-06-25 |
| Dr. Menghisteab Bairu | Director | Appointed | 2025-06-25 |
| Dr. Irit Arbel | Director | Appointed | 2025-06-25 |
| Dr. Hartoun Hartounian | Executive Vice President and Chief Operating Officer | Appointed | 2024-06-20 |
| Stacy Lindborg | member of the Board | Appointed | 2024-04-17 |
| Stacy Lindborg | Co-Chief Executive Officer | Resigned | 2024-04-17 |
| Nir Naor | member of the Board | Appointed | 2023-06-20 |
| Malcolm Taub | member of the Company's Board, and all committees thereof | Resigned | 2023-06-20 |
| David Setboun, PhD, MBA | Executive Vice President and Chief Operating Officer | Resigned | 2023-05-24 |
| Ralph Kern | President and Chief Medical Officer | Retired | 2023-01-04 |